Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT05205109 is registered in ClinicalTrials.gov with Antengene Therapeutics Limited as lead sponsor.

NCT NCT05205109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05205109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Antengene Therapeutics Limited
Phase
Phase 1
Overall status
Recruiting
Start date
June 7, 2022
Completion date
February 28, 2028
Enrollment
98 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic solid tumors